SynthesisFrontiers in immunology2025
Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-driven dual-task prediction model for co-stratifying efficacy and toxicity in NSCLC immunotherapy.PLOS digital health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) improve survival in advanced cancers but are associated with immune-related adverse events (irAEs), whose prognostic impact remains debated. The role of systemic inflammatory biomarkers is also not fully defined. Methods: This research merged a comprehensive systematic review and meta-analysis of 38 studies involving 55,966 participants with a multicenter retrospective cohort study of 870 patients receiving ICI therapy. The aim of this study was to examine the association between irAE characteristics and severity, and baseline inflammatory indicators (NLR, dNLR and PLR), with clinical outcomes, particularly survival (OS) and disease progression survival (PFS). The data were analyzed through time-dependent cox model and meta-analysis. Results: Among 870 immunotherapy patients, 32.4% developed irAEs, predominantly grade 1-2 (83.9%). Severe irAEs (grade >2) significantly increased mortality (OS HR = 1.93). Organ-specific analysis identified endocrine (HR = 0.938, p < 0.001) and skin toxicity (HR = 0.763, p<0.001) as independent protective factors for OS, while hepatic (HR = 1.602, p=0.031) and cardiac toxicity (HR = 1.181, p=0.017) were risk factors. Elevated baseline inflammatory markers-MLR >0.47 (HR = 3.37), NLR >3.45 (HR = 2.24), and PLR >186.98 (HR = 2.10)-also predicted poorer OS. A meta-analysis confirmed that low-grade irAEs (grade ≤2) conferred significant survival benefit (OS HR = 0.54), particularly skin and endocrine toxicities. These findings support irAEs as biomarkers of immunotherapy response, with prognostic relevance shaped by severity and organ involvement. Conclusions: The prognosis of irAEs depends on organ involvement and severity. Endocrine and skin toxicities confer survival benefits, while severe, hepatic, and cardiac events pose significant risks. Inflammatory markers predict survival but not irAE onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.